Yee D, Sharma J, Hilsenbeck S G
Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7884.
J Natl Cancer Inst. 1994 Dec 7;86(23):1785-9. doi: 10.1093/jnci/86.23.1785.
Cellular proliferation, as measured by S-phase fraction, is an important predictor of breast cancer prognosis. The insulin-like growth factors (IGFs) have been shown to regulate proliferation in both normal and neoplastic cells by interacting with specific cell surface receptors. In addition to these receptors, high-affinity extracellular binding proteins also modulate IGF action. These insulin-like growth factor-binding proteins (IGFBPs) could influence breast cancer growth and, like other biological parameters of proliferation, could be related to prognosis.
To test whether IGFBP expression was related to other biological parameters and disease-free survival, we measured IGFBP expression in 238 lymph node-negative primary breast cancer specimens.
Proteins were extracted from breast cancer specimens and analyzed by semiquantitative IGF-I ligand blotting for IGFBP expression. IGFBP expression levels were compared to tumor size, age, S-phase fraction, DNA ploidy, and estrogen and progesterone receptor expression by Spearman correlation.
Binding protein (BP)-2, BP-3, BP-4, and BP-5 were identified in breast cancer extracts. Estrogen receptor expression was positively correlated with BP-2 (Spearman correlation coefficient, rs = .262; P = .0001), BP-4 (rs = .313; P = .0001), and BP-5 (rs = .242; P = .0002). Similar correlations between progesterone receptor and BP-2, BP-4, and BP-5 were also found. BP-3 was inversely correlated with age (rs = -.251, P = .0001). BP-4 was weakly inversely correlated with tumor size (rs = -.141; P = .0295) and S-phase fraction (rs = -.216; P = .0025). Since tumor size and S-phase fraction are powerful predictors of prognosis in node-negative breast cancer, we examined the value of BP-4 as a predictor of disease-free survival. When stratified by tumor size, patients with large (> 2 cm) tumors that expressed low levels of BP-4 had improved survival when compared with patients with large tumors and high BP-4 levels (P = .001).
IGFBPs can be detected in breast cancer specimens, and their level of expression correlates with other known biological parameters of breast cancer. Large tumors with low levels of BP-4 have relatively favorable prognoses.
These data suggest that the IGFBPs may play a role in breast cancer biology and that BP-4 levels, analyzed in conjunction with tumor size, may have prognostic significance.
通过S期分数测量的细胞增殖是乳腺癌预后的重要预测指标。胰岛素样生长因子(IGFs)已被证明可通过与特定细胞表面受体相互作用来调节正常细胞和肿瘤细胞的增殖。除了这些受体外,高亲和力细胞外结合蛋白也可调节IGF的作用。这些胰岛素样生长因子结合蛋白(IGFBPs)可能影响乳腺癌的生长,并且与其他增殖生物学参数一样,可能与预后相关。
为了检测IGFBP表达是否与其他生物学参数和无病生存期相关,我们在238例淋巴结阴性原发性乳腺癌标本中测量了IGFBP表达。
从乳腺癌标本中提取蛋白质,并通过半定量IGF-I配体印迹分析IGFBP表达。通过Spearman相关性分析将IGFBP表达水平与肿瘤大小、年龄、S期分数、DNA倍体以及雌激素和孕激素受体表达进行比较。
在乳腺癌提取物中鉴定出结合蛋白(BP)-2、BP-3、BP-4和BP-5。雌激素受体表达与BP-2(Spearman相关系数,rs = 0.262;P = 0.0001)、BP-4(rs = 0.313;P = 0.0001)和BP-5(rs = 0.242;P = 0.0002)呈正相关。在孕激素受体与BP-2、BP-4和BP-5之间也发现了类似的相关性。BP-3与年龄呈负相关(rs = -0.251,P = 0.0001)。BP-4与肿瘤大小(rs = -0.141;P = 0.0295)和S期分数(rs = -0.216;P = 0.0025)呈弱负相关。由于肿瘤大小和S期分数是淋巴结阴性乳腺癌预后的有力预测指标,我们研究了BP-4作为无病生存期预测指标的价值。按肿瘤大小分层时,与大肿瘤且BP-4水平高的患者相比,大肿瘤(>2 cm)且BP-4表达水平低的患者生存期有所改善(P = 0.001)。
在乳腺癌标本中可检测到IGFBPs,其表达水平与乳腺癌其他已知生物学参数相关。BP-4水平低的大肿瘤预后相对较好。
这些数据表明IGFBPs可能在乳腺癌生物学中发挥作用,并且结合肿瘤大小分析的BP-4水平可能具有预后意义。